160 research outputs found

    STAT1 activation in association with JAK2 exon 12 mutations

    Get PDF
    La inclusi√≥n de la perspectiva de g√©nero en la actividad jurisdiccional es una demanda sostenida de los colectivos feministas y de mujeres, dado que las sentencias tienen un poder performativo y env√≠an un mensaje a la sociedad: ‚Äú[‚Ķ] tienen un poder individual y colectivo que impactan en la vida de las personas y conforman la identidad del poder judicial como un actor imprescindible en la construcci√≥n de un Estado democr√°tico de derecho‚ÄĚ (Suprema Corte de Justicia de la Naci√≥n, 2013:7). La incorporaci√≥n de la perspectiva de g√©nero viene a garantizar la igualdad de posiciones (Kessler, 2014) entre mujeres y varones como una meta, trascendiendo la mera igualdad de oportunidades que hasta el presente se ha demostrado insuficiente para que las mujeres consigamos una ciudadan√≠a plena. Al momento de incorporar la perspectiva de g√©nero en las sentencias, quienes juzgan deben tener presente en primer lugar, el impacto diferenciado de las normas en base al sexo de las personas. En segundo lugar, la interpretaci√≥n y aplicaci√≥n de las leyes en relaci√≥n con (y en base a) estereotipos de g√©nero. Si, por ejemplo, quienes imparten justicia no tienen presentes los estereotipos de g√©nero vigentes detr√°s de las violaciones a los derechos humanos de las mujeres, si no los detectan ni cuestionan, entonces los reproducen. Tal como sostiene Scott (1996) el g√©nero es una categor√≠a imprescindible para el an√°lisis social. En tercer lugar, al momento del juzgamiento, se deben tener en cuenta las exclusiones legitimadas por la ley por pensar el mundo en t√©rminos binarios y androc√©ntricos; en cuarto lugar, la distribuci√≥n no equitativa de recursos y poder que opera entre varones y mujeres en el marco de una organizaci√≥n social patriarcal, y, por √ļltimo, el trato diferenciado por g√©nero legitimado por las propias leyes.Eje 3: Tramas violentas y espacios de exclusi√≥n.Instituto de Cultura Jur√≠dic

    Checking the list: Can a model of Down syndrome help us explore the intellectual accessibility of Heritage sites?

    Get PDF
    There is currently a lack of provision for, and research into, the intellectual accessibility of heritage sites. This paper explores some possible ways forward. It examines recent research with people described as having Down syndrome and uses the syndrome's identified characteristics to create good practice guidelines. It assesses these guidelines against an audio tour written for people with learning difficulties. In conclusion, the paper suggests that drawing upon a generalised model of Down syndrome and these good practice guidelines will allow sites to identify some potential barriers and enablers to intellectual accessibility, but that fully to appreciate the effectiveness of their provision they must still institute site?specific research by people with learning difficulties

    The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

    Get PDF
    Purpose: Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib, a next-generation selective Bruton tyrosine kinase inhibitor, in patients with relapsed/ refractory (R/R) MZL. Patients and Methods: Patients with R/R MZL were enrolled in the phase II MAGNOLIA (BGB-3111-214) study. The primary endpoint was overall response rate (ORR) as determined by an independent review committee (IRC) based on the Lugano 2014 classification. Results: Sixty-eight patients were enrolled. After a median follow-up of 15.7 months (range, 1.6 to 21.9 months), the IRCassessed ORR was 68.2% and complete response (CR) was 25.8%. The ORR by investigator assessment was 74.2%, and the CR rate was 25.8%. The median duration of response (DOR) and median progression-free survival (PFS) by independent review was not reached. The IRC-assessed DOR rate at 12 months was 93.0%, and IRC-assessed PFS rate was 82.5% at both 12 and 15 months. Treatment was well tolerated with the majority of adverse events (AE) being grade 1 or 2. The most common AEs were diarrhea (22.1%), contusion (20.6%), and constipation (14.7%). Atrial fibrillation/flutter was reported in 2 patients; 1 patient had grade 3 hypertension. No patient experienced major hemorrhage. In total, 4 patients discontinued treatment due to AEs, none of which were considered treatment-related by the investigators. Conclusions: Zanubrutinib demonstrated highORRand CR rate with durable disease control and a favorable safety profile in patients with R/R MZL. _2021 The Authors; Published by the American Association for Cancer Research

    Subcutaneous Rituximab-MiniCHOP compared with subcutaneous Rituximab-MiniCHOP plus Lenalidomide in diffuse large B-Cell lymphoma for patients age 80 years or older.

    Full text link
    peer reviewedPURPOSE The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse than that of young patients. An attenuated dose of chemotherapy‚ÄĒcyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-miniCHOP)‚ÄĒis a good compromise between efficacy and safety in very elderly patients. In combination with R-CHOP (R2-CHOP), lenalidomide has an acceptable level of toxicity and may mitigate the negative prognosis of the non‚Äďgerminal center B-cell‚Äďlike phenotype. The Lymphoma Study association conducted a multicentric, phase III, open-label, randomized trial to compare R-miniCHOP and R2- miniCHOP. PATIENTS AND METHODS Patients of age 80 years or older with untreated DLBCL were randomly assigned into the R-miniCHOP21 group or the R2-miniCHOP21 group for six cycles and stratified according to CD10 expression and age. The first cycle of rituximab was delivered by IV on D1 after a prephase and then delivered subcutaneously on D1 of cycles 2-6. Lenalidomide was delivered at a dose of 10 mg once daily on D1-D14 of each cycle. The primary end point was overall survival (OS). RESULTS A total of 249 patients with new DLBCL were randomly assigned (127 R-miniCHOP and 122 R2- miniCHOP). The median age was 83 years (range, 80-96), and 55% of the patients were classified as non-GCB. The delivered dose for each R-miniCHOP compound was similar in both arms. Over a median follow-up of 25.1 months, the intention-to-treat analysis revealed that R2-miniCHOP did not improve OS (2-year OS 66% in R-miniCHOP and 65.7% in R2-miniCHOP arm, P5 .98) in the overall population or in the non-GCB population. Grade 3-4 adverse events occurred in 53% of patients with R-miniCHOP and in 81% of patients with R2- miniCHOP. CONCLUSION The addition of lenalidomide to R-miniCHOP does not improve OS. Rituximab delivered subcutaneously was safe in this population

    An√°lise situacional de comunidades extrativistas de castanha¬≠-da-amaz√īnia.

    Get PDF
    Resumo: A castanheira-da¬≠-amaz√īnia (Bertholletia excelsa Bonpl.) est√° presente em v√°rias √°reas do espa√ßo amaz√īnico brasileiro. Esses espa√ßos possuem hist√≥rias de ocupa√ß√£o humana que se diferenciaram ao longo do tempo, conferindo diversidade de perfis socioecon√īmicos e formas de intera√ß√£o com a natureza no que se refere ao uso e √† extra√ß√£o de recursos naturais. Com o objetivo de diagnosticar as tipologias de produ√ß√£o da castanha¬≠&-da¬≠-amaz√īnia e o uso dos territ√≥rios por diferentes grupos sociais em estruturas fundi√°rias distintas na Amaz√īnia brasileira, este cap√≠tulo apresenta o perfil de comunidades extrativistas onde o projeto de pesquisa ?Ecologia e gen√©tica da castanheira (Bertholletia excelsa Bonpl.) como subs√≠dio √† conserva√ß√£o e uso sustent√°vel da esp√©cie? realizou a√ß√Ķes nos estados de Roraima, do Amazonas, do Par√° e do Amap√°.V.1 - Aspectos sociais, econ√īmicos e organizacionais. ODS 2, ODS 8, ODS 10

    Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

    Get PDF
    Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low‚Äďmiddle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‚Äėsingle-use‚Äô consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low‚Äďmiddle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high‚Äď and low‚Äďmiddle‚Äďincome countries

    Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries